As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of ESSA Pharma Inc. The largest reported stake is Soleus Capital Master Fund, L.P.'s, at 9.8%. 7 filings are on record since July 21, 2025 (Schedule 13D/A, July 21, 2025).
Sell to companies like ESSA Pharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: Tang Capital Management, LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: Tang Capital Management, LLC · Percent: 0% · SCHEDULE 13G/A
- · Holder: Biotechnology Value Fund L P · Percent: 0% · SCHEDULE 13D/A
- · Holder: Morgan Stanley · Percent: 4% · SCHEDULE 13G/A
- · Holder: Biotechnology Value Fund L P · Percent: 24.7% · SCHEDULE 13D/A
ESSA Pharma Inc. has 7 Schedule 13D or 13G filings on record since 2025-07-21. 1 holder's latest filing reports 5% or more of common shares, no par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Soleus Capital Master Fund, L.P. | 9.8% | 4,362,026 | SCHEDULE 13D/A, 2025-07-21 | 2025-07-17 |
| 4% | 1,904,062 | SCHEDULE 13G/A, 2025-10-07 | 2025-09-30 | |
| Tang Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
| Biotechnology Value Fund L P | 0% | 0 | SCHEDULE 13D/A, 2025-10-14 | 2025-10-09 |
Holding shares or following this stake? See who's behind ESSA Pharma Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on ESSA Pharma Inc. and the records around it.
Companies that share a holder
- SOLEUS CAPITAL MASTER FUND, L.P. also filed stake reports on 24 other companies: Beta Bionics, Inc. (Nov 2026), Evolus, Inc (Nov 2026), INSPIRE MEDICAL SYSTEMS, INC. (Nov 2026)
- TANG CAPITAL MANAGEMENT, LLC also filed stake reports on 33 other companies: EyePoint, Inc. (Oct 2026), Skye Bioscience, Inc. (Oct 2026), Nano Dimension Ltd. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Foghorn Therapeutics Inc. (Oct 2026)
Watch ESSA Pharma Inc.
Get an email when ESSA Pharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ESSA Pharma Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ESSA Pharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ESSA Pharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Purpose of Transaction (Item 4)
Biotechnology Value Fund L P
Item 4 is hereby amended to add the following: Effective October 9, 2025, the Issuer was acquired by Xeno Acquisition Corp. (the "Purchaser") pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the "Parent"), Purchaser, a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025 and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding Shares in exchange for: (i) $0.124231 in cash per Share (excluding the approximately $1.69 of cash per Share previously distributed to the Issuer's shareholders) and (ii) one contingent value right per Share for potential cash payments of up to approximately $0.14 per Share. Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer.Item 4 of the SCHEDULE 13D/A filed 2025-10-14
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-07-21 | Soleus Capital Master Fund, L.P. | 9.8% | SCHEDULE 13D/A |
| 2025-07-30 | Tang Capital Management, LLC | 9.7% | SCHEDULE 13G |
| 2025-08-07 | Biotechnology Value Fund L P | 24.7% | SCHEDULE 13D/A |
| 2025-10-07 | Morgan Stanley | 4% | SCHEDULE 13G/A |
| 2025-10-14 | Biotechnology Value Fund L P | 0% | SCHEDULE 13D/A |
| 2025-11-14 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2025-11-14 | Tang Capital Management, LLC | 0% | SCHEDULE 13G/A |
Questions about who owns ESSA Pharma Inc.
Who owns ESSA Pharma Inc.?
On this page, one holder's latest ownership filing reports 5% or more of ESSA Pharma Inc.: Soleus Capital Master Fund, L.P. (9.8%, Schedule 13D/A, filed 2025-07-21).
When did Soleus Capital Master Fund, L.P. buy into ESSA Pharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Soleus Capital Master Fund, L.P. on this page is the Schedule 13D/A, filed 2025-07-21, reporting 9.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for ESSA Pharma Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.